The global cardiac biomarkers market size valued USD 13.08 billion in 2021 and expected to reach USD 25.08 billion by 2028, at a CAGR of 10.08% during the forecast period 2022-2028. Cardiac biomarkers are the substances that usually released into the blood when the heart is stressed or damaged. They are helpful in the diagnosis of an acute coronary syndrome (ACS) and cardiac ischemia, and other conditions associated with insufficient blood flow to the heart. The test for cardiac biomarkers is used to determine an individual’s risk of having the above conditions. A cardiac biomarker is a protein-based molecule that may be quantified for heart disease prognosis and diagnosis. When the heart is injured or stressed, such as from a lack of oxygen, cardiac biomarkers are released into the bloodstream. Cardiovascular biomarkers including cardiac troponin, creatinine kinase, myoglobin, and others are used to diagnose disorders like ACS and heart ischemia.